Multiple recently launched products—Winrevair in PAH, Welireg in RCC, Capvaxive in pneumococcal disease, Ohtuvayre in COPD—are scaling rapidly enough to diversify revenue away from Keytruda concentration and offset declining franchises like Januvia/Janumet.
the thesis · admitted · the reason above is the thesis, not printed twice
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedsix sentences · whole, uncut
the claims it rests on · in our words, not the filing’s
Sales of Winrevair rose 75% and 81% in the second quarter and first six months of 2026, respectively, largely due to continued uptake in the U.S. and early launch uptake in certain international markets